SNWV · XBRL financial data

SANUWAVE Health financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SNWV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	4,953	6,994*	5,786	7,162	9,360	10,326*	9,342	10,164	11,451	13,094*	9,619	9,739
Revenue from contracts with customers	4,821	6,528*	5,684	7,078	9,291	10,278*	9,291	10,147	11,422	—	—	—
Cost of revenue	1,412	2,159*	1,584	1,922	2,293	2,285*	1,958	2,206	2,526	3,392*	2,188	2,315
Gross profit	3,541	4,835*	4,202	5,240	7,067	8,041*	7,384	7,958	8,925	9,702*	7,431	7,424
Research and development	165	143*	163	195	161	154*	208	194	345	606*	660	628
General and administrative	2,681	1,996*	3,675	1,839	2,545	3,289*	4,467	4,039	4,810	6,056*	5,250	4,902
Total operating expenses	4,072	3,796*	5,252	3,248	5,114	5,519*	6,398	6,081	7,458	9,087*	8,555	7,704
Operating income (loss)	(531)	1,039*	(1,050)	1,992	1,953	2,522*	986	1,877	1,467	615*	(1,124)	(280)
Interest expense	—	—	3,263	3,426	3,353	2,523*	1,909	1,939	1,795	—	546	518
Other income (expense)	(23,169)	17,200*	(3,478)	4,569	(22,610)	(15,243)*	(6,662)	(822)	8,858	5,580*	(315)	(396)
Income tax expense (benefit)	0	4*	—	—	—	year only	—	0	—	year only	—	6
Net income (loss)	(23,700)	18,235*	(4,528)	6,561	(20,657)	(12,748)*	(5,676)	1,055	10,325	6,109*	(1,439)	(682)
Earnings per share, basic‡ USD per share	(11.11)	—	0.00	3.70	(2,403.70)	—	(0.66)	0.12	1.20	0.71*	(0.17)	(0.08)
Earnings per share, diluted‡ USD per share	(11.11)	—	0.00	0.00	(2,403.70)	—	(0.66)	0.01	0.46	—	(0.17)	(0.08)
Weighted average shares, basic‡ thousands of shares	2,411	—	3,138	3,193	9	—	8,548	8,562	8,571	8,573*	8,591	8,601
Weighted average shares, diluted‡ thousands of shares	2,411	—	3,138	3,747	9	—	8,548	9,168	9,141	9,463*	8,591	8,601

‡ Per-share figures and share counts are adjusted for the 1-for-370.3703703703703 stock split (October 2024); filings made before it reported them unadjusted.
† Share count changed about 1/138 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 371x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (SNWV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,095	1,797	2,936	2,460	3,259	10,237	8,501	8,496	9,602	11,959	10,779	9,376
Accounts receivable	3,231	3,314	3,008	3,154	2,836	3,329	3,866	3,848	4,620	5,422	6,000	5,801
Inventory	1,713	2,951	2,461	2,731	3,431	4,149	5,457	5,911	6,814	5,934	5,903	7,070
Prepaid and other current assets	1,355	1,722	2,426	379	378	682	1,007	1,913	1,597	1,312	1,274	954
Total current assets	7,394	9,784	10,831	8,724	9,904	18,397	18,831	20,168	22,633	24,627	23,956	23,201
Property and equipment, net	1,079	938	975	947	774	732	449	1,587	1,994	1,972	1,913	2,255
Right-of-use asset	—	—	—	—	—	429	761	653	431	390	991	953
Goodwill	7,260	7,260	7,260	7,260	7,260	7,260	7,260	7,260	7,260	7,260	7,260	7,260
Total assets	20,342	22,416	23,324	21,013	21,844	30,119	30,855	33,046	35,599	37,343	37,097	36,605
Accounts payable	4,623	5,705	5,062	3,891	4,137	3,728	4,151	4,002	3,992	3,251	3,320	3,308
Accrued liabilities	6,359	5,999	6,849	4,794	5,241	4,678	3,581	3,289	3,586	8,382	8,584	8,605
Current portion of long-term debt	—	—	—	—	—	—	—	—	5,750	5,750	5,750	—
Total current liabilities	85,434	64,755	70,184	59,965	81,513	42,345	47,268	46,501	19,577	17,847	18,304	18,173
Long-term debt	—	—	—	—	—	—	—	—	17,534	16,142	14,762	—
Total liabilities	86,296	65,594	70,919	60,619	82,107	42,836	48,147	47,821	38,530	35,724	35,259	33,818
Accumulated deficit	(238,284)	(220,049)	(224,577)	(218,016)	(238,673)	(251,421)	(257,097)	(256,042)	(245,717)	(242,685)	(244,124)	(244,806)
Total stockholders' equity	(65,954)	(43,178)	(47,595)	(39,606)	(60,263)	(12,717)	(17,292)	(14,775)	(2,931)	1,619	1,838	2,787
Total liabilities and equity	20,342	22,416	23,324	21,013	21,844	30,119	30,855	33,046	35,599	37,343	37,097	36,605
Common shares outstanding (cover page)‡ thousands of shares	2,770	3,080	3,094	3,189	23	8,548	8,556	8,568	8,576	8,594	8,599	8,602

‡ Per-share figures and share counts are adjusted for the 1-for-370.3703703703703 stock split (October 2024); filings made before it reported them unadjusted.
† Share count changed about 1/138 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 371x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (SNWV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(23,700)	18,235*	(4,528)	6,561	(20,657)	(12,748)*	(5,676)	1,055	10,325	6,109*	(1,439)	(682)
Stock-based compensation	—	year only	0	0*	0*	1,514*	975	1,131*	1,407*	1,337*	1,611	1,532*
Depreciation and amortization	265*	248*	218	262*	256*	409*	209	179*	246*	340*	294	313*
Net cash from operating activities	(2,038)*	(1,285)*	1,100	(668)*	1,282*	741*	(1,517)	993*	1,081*	year only	397	425*
Purchases of property and equipment	0*	(169)*	114	92*	48*	236*	162	1,159*	525*	96*	23	334*
Net cash from investing activities	13*	177*	(114)	(92)*	(48)*	(236)*	(162)	(1,159)*	4,475*	279*	(158)	(448)*
Proceeds from issuing common stock	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from financing activities	1,930*	1,855*	42	274*	(435)*	6,473*	(57)	161*	(4,450)*	(1,241)*	(1,419)	(1,379)*
Net change in cash	(87)*	702*	1,139	(476)*	799*	6,978*	(1,736)	(5)*	1,106*	2,357*	(1,180)	(1,403)*

† Share count changed about 1/138 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 371x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
SANUWAVE Health	9,376	9,739	425*	8.6M	—	Q2 FY26 10-QJun 30, 2026
Cerus	16,350	57,714	3,007*	202.0M	—	Q3 FY26 10-QSep 30, 2026
Electromed	20,450	19,417*	2,994*	8.4M	—	Q4 FY26 10-KJun 30, 2026
Tactile Systems Technology	75,110	91,858	11,978*	22.4M	—	Q3 FY26 10-QSep 30, 2026
Orasure Technologies	160,582	30,639	(9,921)*	69.0M	16.2 quarters	Q2 FY26 10-QJun 30, 2026
Bioventus	30,709	142,442	20,658*	not reported	—	Q3 FY26 10-QSep 26, 2026
Treace Medical Concepts	12,610	45,376	(4,698)*	65.0M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
SS Innovations International	13,647	not reported	(4,235)*	200.4M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Inogen	87,276	95,084	2,946*	26.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.